NPCE - NeuroPace Inc

QQQ $ 429.07 $ 5.38 (1.28 %)

DIA $ 382.31 $ 3.34 (0.88 %)

SPY $ 505.01 $ 4.68 (0.94 %)

TLT $ 88.87 $ 0.38 (0.43 %)

GLD $ 213.12 $ -0.66 (-0.31 %)

Previous Close

$ 13.9

Open

$ 13.80

Bid

$ 0.00 x 0

Ask

$ 0.00 x 0

Day's Range

$ 13.79 - $ 14.06

52 Week Range

$ 3.80 - $ 18.15

Volume

50,174

Average Volume

Market Cap

359.34M

Beta (5Y Monthly)

$ 1.34

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	03-05-2024	12-31-2023	10-K
2	11-06-2023	09-30-2023	10-Q
3	08-08-2023	06-30-2023	10-Q
4	05-04-2023	03-31-2023	10-Q
5	03-02-2023	12-31-2022	10-K
6	11-08-2022	09-30-2022	10-Q
7	08-11-2022	06-30-2022	10-Q
8	05-12-2022	03-31-2022	10-Q
9	03-10-2022	12-31-2021	10-K
10	11-10-2021	09-30-2021	10-Q
11	08-12-2021	06-30-2021	10-Q
12	06-03-2021	03-31-2021	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Wells Fargo Upgrades NeuroPace to Overweig...
03/14/2024 13:18:38

Wells Fargo analyst Lawrence Biegelsen upgrades NeuroPace (NASDAQ:NPCE) from Equal-Weight to Overweight and raises the price...

The Latest Analyst Ratings For NeuroPace
03/12/2024 14:00:46

JP Morgan Maintains Overweight on NeuroPac...
03/12/2024 13:07:31

JP Morgan analyst Robbie Marcus maintains NeuroPace (NASDAQ:NPCE) with a Overweight and raises the price target from $9 to $17.

Cantor Fitzgerald Maintains Overweight on ...
03/06/2024 17:28:17

Cantor Fitzgerald analyst Ross Osborn maintains NeuroPace (NASDAQ:NPCE) with a Overweight and raises the price target from $...

Morgan Stanley Maintains Equal-Weight on N...
03/06/2024 17:15:12

Morgan Stanley analyst Drew Ranieri maintains NeuroPace (NASDAQ:NPCE) with a Equal-Weight and raises the price target from $...

NeuroPace Provides Full-year 2024 Revenue ...
03/05/2024 22:28:00

Gross margin to range between 72% and 74%, Total operating expenses to range between $80 million and $84 million, including app...

Recap: NeuroPace Q4 Earnings
03/05/2024 21:35:06

NeuroPace Q4 2023 GAAP EPS $(0.23) Beats $...
03/05/2024 21:32:58

NeuroPace (NASDAQ:NPCE) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.32) by ...

Earnings Scheduled For March 5, 2024
03/05/2024 10:00:02

Companies Reporting Before The Bell • NIO (NYSE:NIO) is estimated to report quarterly loss at $0.51 per share on revenue of $2...

Earnings Preview: NeuroPace
03/04/2024 17:01:14

A Glimpse Into The Expert Outlook On Neuro...
02/22/2024 17:00:36

NeuroPace Stock: A Deep Dive Into Analyst ...
01/30/2024 14:00:14

Leerink Partners Initiates Coverage On Neu...
01/30/2024 13:15:02

Leerink Partners analyst Mike Kratky initiates coverage on NeuroPace (NASDAQ:NPCE) with a Outperform rating and announces Pr...

NeuroPace Sees Prelim. Q4 Revenue $17.5M-$...
01/08/2024 12:30:16

Breaking Down NeuroPace: 6 Analysts Share ...
12/27/2023 15:00:24

Lake Street Reiterates Buy on NeuroPace, M...
12/27/2023 14:29:32

Lake Street analyst Frank Takkinen reiterates NeuroPace (NASDAQ:NPCE) with a Buy and maintains $12 price target.

NeuroPace Disclosed The Completion Of The ...
12/21/2023 12:08:47

NeuroPace Announces Strategic Collaboratio...
12/04/2023 22:09:53

This collaboration will evaluate biomarker changes in currently implanted RNS System patients that have enrolled in a clinical-...

Neuropace Entered Collaboration With Rappo...
12/04/2023 22:09:23

-8-K

Expert Ratings for NeuroPace
12/04/2023 18:00:19